# International Society for Oncology and Biomarkers (ISOBM)

> organisation involved in scholarly research

**Wikidata**: [Q74552192](https://www.wikidata.org/wiki/Q74552192)  
**Source**: https://4ort.xyz/entity/international-society-for-oncology-and-biomarkers-isobm

## Summary
The International Society for Oncology and Biomarkers (ISOBM) is a UK-based research institute dedicated to advancing scholarly research in oncology and biomarkers, with a specialized focus on tumor biology. It contributes to the field through academic initiatives and associations with key publications.

## Key Facts
- Based in the United Kingdom.
- Classified as a research institute with a focus on tumor biology.
- Affiliated with the journal *Tumor Biology*, published by SAGE Publications.
- Engages in scholarly research initiatives in oncology and biomarkers.
- No founding date or creator information is available in the provided sources.

## FAQs
### Q: What is the primary focus of the International Society for Oncology and Biomarkers (ISOBM)?
A: The ISOBM specializes in research related to oncology, biomarkers, and tumor biology, aiming to advance scientific understanding and applications in these areas.

### Q: Where is the ISOBM based?
A: The organization is headquartered in the United Kingdom.

### Q: Is the ISOBM associated with any academic publications?
A: Yes, it is affiliated with the journal *Tumor Biology*, which publishes peer-reviewed research in the field.

## Why It Matters
The ISOBM plays a critical role in fostering collaboration and knowledge dissemination in oncology and biomarker research. By concentrating on tumor biology, it addresses a foundational aspect of cancer research, which is essential for developing diagnostic tools, therapies, and personalized treatment strategies. Its association with *Tumor Biology* underscores its commitment to rigorous academic publishing, ensuring that cutting-edge findings reach global audiences. This work directly impacts healthcare by bridging scientific discovery with clinical applications, ultimately improving outcomes for cancer patients.

## Notable For
- Specialization in tumor biology research, a cornerstone of modern oncology.
- Strategic affiliation with the journal *Tumor Biology*, enhancing the reach and credibility of its scholarly contributions.
- Dedication to advancing biomarker science, which is vital for early cancer detection and targeted therapies.
- Role as a UK-based hub for international research collaboration in oncology.

## Body
### Research Focus
The ISOBM prioritizes research in **tumor biology**, emphasizing the study of biological processes underlying cancer development and progression. This includes investigations into biomarkers—molecules or genes indicative of specific conditions—which are critical for early diagnosis, prognosis, and treatment response monitoring.

### Affiliation and Publications
A key distinction of the ISOBM is its affiliation with the journal ***Tumor Biology***, a SAGE Publications title. This relationship facilitates the dissemination of high-impact research, ensuring that studies undergo rigorous peer review and reach a broad academic and clinical audience. The journal’s scope aligns with the ISOBM’s mission, covering topics such as oncogenes, tumor microenvironments, and biomarker validation.

### Geographical and Institutional Context
Headquartered in the **United Kingdom**, the ISOBM operates within a global network of research institutions. While specific founding dates or leadership details are not provided in the source material, its classification as a research institute underscores its role as a dedicated entity for scientific inquiry, distinct from academic universities or healthcare providers.

### Scholarly Impact
By engaging in and promoting scholarly research, the ISOBM contributes to the translation of basic science into clinical practice. Its work supports the development of personalized medicine approaches, where biomarkers help tailor treatments to individual patient profiles, reducing side effects and improving efficacy. This aligns with broader efforts in the oncology community to shift from generalized therapies to targeted interventions.

## References

1. [Directory of Open Access Journals](https://uk.sagepub.com/en-gb/eur/tumor-biology/journal202707#submission-guidelines)